Acute Kidney Injury Market Poised for Significant Growth Through 2036 Driven by Emerging Therapies and Expanding Patient Burden

The Acute Kidney Injury (AKI) market is expected to witness notable growth during the forecast period, fueled by the increasing prevalence of kidney-related complications, growing awareness regarding critical care nephrology, and the anticipated launch of innovative pipeline therapies. Advancements in targeted therapeutics and improved diagnostic technologies are further expected to transform the Acute Kidney Injury treatment landscape across major global markets.
According to DelveInsight's Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2036 report, the market study delivers a comprehensive understanding of Acute Kidney Injury, including historical and forecasted epidemiology, market trends, emerging therapies, competitive intelligence, and treatment patterns across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
The report evaluates current treatment practices, market size, evolving therapeutic approaches, and emerging opportunities expected to influence the AKI market from 2020 to 2036.

Key Takeaways from the Acute Kidney Injury Market Report
• In November 2025, Mallinckrodt announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectable businesses. Following the transition, the company will operate as Keenova Therapeutics, focusing on branded therapeutics for rare and underserved diseases.
• In October 2025, AM-Pharma announced that topline data from the Phase II clinical trial evaluating ilofotase alfa for Cardiac Surgery-associated Renal Damage (CSA-RD) prevention is expected in early 2026, with plans to initiate a pivotal Phase III study thereafter.
• The Acute Kidney Injury market is projected to grow at a significant CAGR during the study period (2020-2036), primarily driven by rising patient burden and expected approvals of emerging therapies.
• The Acute Kidney Injury market size was estimated at approximately USD 4,900 million in 2025 and is projected to expand substantially by 2034.
• Increasing hospitalization rates, sepsis incidence, cardiovascular surgeries, and critical care admissions continue to contribute significantly to AKI prevalence globally.

Stay ahead in the evolving AKI therapeutics landscape with DelveInsight's comprehensive market intelligence report: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Acute Kidney Injury Overview
Acute Kidney Injury (AKI), previously referred to as acute renal failure, is characterized by a sudden decline in kidney function occurring over hours to days. The condition results in the accumulation of waste products, electrolyte imbalance, and impaired fluid regulation within the body.
AKI commonly develops in hospitalized and critically ill patients due to factors such as sepsis, major surgeries, dehydration, nephrotoxic drugs, trauma, and chronic underlying diseases. Early diagnosis and timely intervention remain crucial to reducing mortality and long-term complications associated with AKI.

Acute Kidney Injury Epidemiology Insights
The epidemiology section of the report provides detailed insights into historical, current, and forecasted patient populations across the 7MM. The analysis examines disease burden trends, diagnosed cases, and key factors influencing AKI prevalence and incidence across different geographies.
The report also evaluates epidemiological assumptions, healthcare trends, and expert opinions to better understand evolving patient dynamics in Acute Kidney Injury.
Download the report to explore the factors driving Acute Kidney Injury epidemiology trends:https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Acute Kidney Injury Drugs Market
The Acute Kidney Injury drugs market is expected to experience substantial expansion over the coming years as several targeted therapies advance through late-stage clinical development and gain regulatory approval.
Ongoing research focused on inflammatory pathways, ischemia-reperfusion injury, oxidative stress, and renal repair mechanisms is anticipated to open new opportunities for innovative AKI therapeutics.

Acute Kidney Injury Treatment Market Landscape
The AKI treatment landscape has evolved significantly with advancements in renal replacement therapies, biologics, anti-inflammatory agents, and regenerative medicine approaches. Novel therapies targeting kidney tissue protection and repair mechanisms are gaining considerable attention in the nephrology market.
Emerging therapeutic approaches are expected to improve patient outcomes while addressing significant unmet needs associated with severe AKI complications and high mortality rates.
Learn more about Acute Kidney Injury treatment strategies and therapeutic advancements:https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Acute Kidney Injury Market Outlook
The Acute Kidney Injury market outlook section provides detailed analysis of historical, existing, and forecasted market trends. The report evaluates the impact of current treatment standards, emerging pipeline therapies, market drivers, barriers, and evolving healthcare technologies shaping the AKI market.
The assessment also includes detailed evaluation of late-stage pipeline products expected to influence future market dynamics and competitive positioning.

Acute Kidney Injury Drug Uptake and Pipeline Development
The report offers comprehensive analysis of marketed and emerging Acute Kidney Injury therapies, including:
• Clinical trial developments
• Pharmacological mechanisms
• Regulatory milestones
• Collaborations and licensing agreements
• Patent intelligence
• Advantages and limitations of pipeline therapies
• Recent press releases and corporate developments

Leading Acute Kidney Injury Companies
• Fresenius Medical Care
• Baxter International
• Medtronic
• B. Braun Melsungen AG
• Nikkiso Co., Ltd.
• Nipro Corporation
• Asahi Kasei Medical
• Guard Therapeutics
• Quark Pharmaceuticals
• Angion Biomedica Corp.
• Pharmazz, Inc.
• DURECT Corporation
• Kringle Pharma
• bioMérieux
• BioPorto Diagnostics
• Maze Therapeutics
• Sentien Biotechnologies

Promising Acute Kidney Injury Pipeline Therapies
• Terlipressin (TERLIVAZ)
• RBT-1
• Ravulizumab
• ilofotase alfa

Explore ongoing clinical developments and emerging therapies in AKI: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Acute Kidney Injury Market Drivers
• Increasing incidence of sepsis and critical care admissions
• Growing prevalence of cardiovascular and metabolic disorders
• Rising number of surgical procedures associated with renal complications
• Advancements in renal replacement technologies and biomarkers
• Increasing awareness regarding early AKI diagnosis and intervention
• Growing investments in nephrology-focused drug development

Acute Kidney Injury Market Barriers
• Limited availability of approved targeted therapies
• High mortality and complication rates associated with severe AKI
• Diagnostic challenges in early-stage disease identification
• High healthcare costs associated with hospitalization and dialysis
• Regulatory and clinical trial complexities

Scope of the Acute Kidney Injury Market Report
• Coverage: 7MM
• Study Period: 2020-2036
• Forecast Period: 2024-2036
• Therapeutic Assessment: Marketed and emerging AKI therapies
• Market Dynamics: Drivers, barriers, opportunities, and unmet needs
• Additional Insights: Market access, reimbursement analysis, KOL perspectives, SWOT analysis, and future market outlook

Table of Contents Highlights
• Key Insights
• Executive Summary
• Disease Background and Overview
• Treatment and Prevention
• Epidemiology and Patient Population
• Marketed Therapies
• Emerging Therapies
• AKI 7MM Market Analysis
• Unmet Needs
• SWOT Analysis
• KOL Views
• Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: info@delveinsight.com
Contact No.: +14699457679
Address: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm specializing in life sciences intelligence and strategic business solutions. The company delivers high-quality market insights, epidemiology forecasts, competitive intelligence, and pipeline analysis to support informed decision-making for pharmaceutical, biotechnology, and healthcare organizations worldwide.

This release was published on openPR.